$CTXR News

HC Wainwright & Co. Assumes Citius Pharmaceuticals at Buy, Announces Price Target of $4

Citius Pharmaceuticals shares are trading lower after the company announced a $5 million registered direct offering.

Citius Pharmaceuticals shares are trading lower after the company announced a $5 million registered direct offering.

UPDATE: Reported Earlier, Citius Pharma Prices $5M Offering Of 5,076,143 Shares At A Price Of $0.985/Share

Citius Pharmaceuticals shares are trading higher after the company provided a commercial update on the U.S. launch of LYMPHIR for the treatment of cutaneous T-cell lymphoma.

Citius Pharmaceuticals shares are trading higher after the company announced topline results from investigator‑initiated Phase 1 Study of LYMPHIR in combination with pembrolizumab in relapsed or refractory gynecologic cancers.

Citius Oncology Announces Data From Phase 1 Clinical Study Of Direct T-Regulatory Cell Depletion Activity Of LYMPHIR Shows 24% Objective Response Rate, 48% Clinical Benefit Rate In Participants With Recurrent Or Refractory Gynecologic Cancers

Citius Oncology Announces Topline Results From Investigator‑Initiated Phase 1 Trial Of LYMPHIR Administered Prior To Commercial CD19‑Directed CAR‑T Therapy In High‑Risk DLBCL; Co Says LYMPHIR Was Well-Tolerated With No Dose-Limiting Toxicities Observed

Citius Pharmaceuticals Q1 Earnings Report: What Investors Need to Know

Citius Pharma Q1 EPS $(0.38) Misses $(0.30) Estimate, Sales $3.944M Beat $3.455M Estimate

Citius Pharmaceuticals' Citrus Oncology Enters Into Exclusive Distribution Agreement With Uniphar To Support Access To LYMPHIR Outside U.S.

Citius Pharmaceuticals shares are trading lower. The company reported Q4 results.

Citius Pharmaceuticals (CTXR) Surges 22% After Hours — Here's Why

Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Citius Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 EPS results.

Citius Pharma Q4 EPS $(0.11) Beats $(0.43) Estimate

Citius Pharmaceuticals' Subsidiary Citius Oncology Launches Cancer Immunotherapy, LYMPHIR, In The U.S. In December 2025 For The Treatment Of Adult Patients With Relapsed Or Refractory Stage I-III CTCL After At Least One Prior Systemic Therapy; Co. Raised ~ $61M In Gross Proceeds From Capital Raises

Citius Oncology Announces Agreement With Investor For Purchase And Sale Of 1,284,404 Shares At $1.09/Share In Registered Direct Offering; Concurrently Enters Agreement For Purchase And Sale Of 15,229,358 Shares Of Common Stock And Warrants To Purchase Up To 15,229,358 Shares At $1.09/Share And Accompanying Warrant

D. Boral Capital Maintains Buy on Citius Pharmaceuticals, Maintains $6 Price Target